<?xml version="1.0" encoding="ISO-8859-1" ?>
<rss version="2.0">
<channel>
<title><![CDATA[Feedzilla.com: Top 20 news stories about industry / Pharmaceuticals]]> </title>
<description><![CDATA[ Feedzilla.com: Top 20 news stories about industry / Pharmaceuticals. Add free content to your site and blog with Feedzilla.com's free widgets. ]]> </description>
<link>http://www.feedzilla.com</link>
<language>en</language>
<lastBuildDate>Sat, 19 Jul 2008 1:00:02 PM EST</lastBuildDate>
<image>
<title>Read News. Syndicate News.</title>
<url>http://www.feedzilla.com/img/logo.gif</url>
<link>http://www.feedzilla.com</link>
</image>
<item>
<title><![CDATA[Earnings Outlook: Weak U.S. dollar should boost Big Pharma earnings]]></title>
<description><![CDATA[Major pharmaceutical companies are expected to roll out higher second-quarter earnings reports in coming days, helped partly by strong overseas sales stoked by a weak U.S. dollar. &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.marketwatch.com/enf/rss.asp?guid=%7BA2543DDA-F85B-49FE-BDC7-BD8E3969EC28%7D&siteid=rss]]></link>
<pubDate>Sat, 19 Jul 2008 10:00:00 -0500</pubDate>
</item>
<item>
<title><![CDATA[AFFiRiS reaches milestone in clinical trial of Alzheimer's vaccine]]></title>
<description><![CDATA[In the clinical phase I trial AFF001, AFFiRiS GmbH has now recruited the 24 Alzheimer patients planned for this trial. The trial aims to investigate the tolerability and safety of an Alzheimer's ... &nbsp; <a href='http://www.feedzilla.com/'>Free content on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.bionity.com/news/e/84908/?WT.mc_id=ca0068]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[BELLUS Health signs agreement to acquire Innodia]]></title>
<description><![CDATA[BELLUS Health Inc. announced that it has signed a definitive agreement to purchase capital stock of Innodia Inc. This will result in the BELLUS Health Group owning 100% of the capital stock, thereby ... &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.bionity.com/news/e/84914/?WT.mc_id=ca0068]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[Boehringer Ingelheim licenses drug targets from autoimmune collaboration with Galapagos]]></title>
<description><![CDATA[Galapagos NV announced that Boehringer Ingelheim has exercised its right to license two drug targets from the autoimmune research agreement with Galapagos' BioFocus DPI service division, resulting in ... &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.bionity.com/news/e/84905/?WT.mc_id=ca0068]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[US Patent for Rapid Test Method and Technology Platform Awarded to MedMira]]></title>
<description><![CDATA[MedMira Inc. announced that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid ... &nbsp; <a href='http://www.feedzilla.com/'>Free RSS news feeds on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.bionity.com/news/e/84915/?WT.mc_id=ca0068]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[ARPKD/CHF Alliance Awards Grant for Fibrosis Research]]></title>
<description><![CDATA[The ARPKD/CHF Alliance (www.arpkdchf.org) is pleased to announce a Research Grant of $50,000 was awarded to Dr. Rebecca Wells, M.D., Assistant Professor of Medicine (Gastroenterology) and Pathology an... [WebWire - Saturday, July 19, 2008] &nbsp; <a href='http://www.feedzilla.com/'>Free content on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.webwire.com/ViewPressRel.asp?aId=70452]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[Boehringer Ingelheim FENS Award for Pascal Fries for his exceptional research in neuroscience]]></title>
<description><![CDATA[Ingelheim/Geneva, July 2008 - The 2008 Boehringer Ingelheim FENS Research Award goes to Pascal Fries, MD, PhD, from the F.C. Donders Centre for Cognitive Neuroimaging in Nijmegen, The Netherlands. Tod... [WebWire - Friday, July 18, 2008] &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.webwire.com/ViewPressRel.asp?aId=70441]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases]]></title>
<description><![CDATA[Potential New Treatment Paradigm, PTC124 -   -  Genzyme Corporation (Nasdaq: GENZ) and PTC Therapeutics, Inc. (PTC) today announced an exclusive global collaboration to develop and commercialize PTC124, P... [WebWire - Friday, July 18, 2008] &nbsp; <a href='http://www.feedzilla.com/'>Free content on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.webwire.com/ViewPressRel.asp?aId=70424]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[As Fires Burn, Red Cross Brings Relief To Weary California]]></title>
<description><![CDATA[A busy disaster season continues with the response to California wildfires -  WASHINGTON, Friday, July  2008 - The California Department of Forestry and Fire Protection today reported 80 active wildfire... [WebWire - Friday, July 18, 2008] &nbsp; <a href='http://www.feedzilla.com/'>Free content on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.webwire.com/ViewPressRel.asp?aId=70413]]></link>
<pubDate>Sat, 19 Jul 2008 06:00:00 EST</pubDate>
</item>
<item>
<title><![CDATA[CTRC recognized as center of excellence in fight against marrow disease]]></title>
<description><![CDATA[The Cancer Therapy &amp; Research Center (CTRC) at the University of Texas Health Science Center at San Antonio has been named a Center of Excellence by the Myelodysplastic Syndromes Foundation. &nbsp; <a href='http://www.feedzilla.com/'>Free RSS news feeds on Feedzilla</a>]]></description>
<link><![CDATA[ http://feeds.bizjournals.com/~r/vertical_36/~3/339324511/daily40.html]]></link>
<pubDate>Fri, 18 Jul 2008 20:32:03 GMT</pubDate>
</item>
<item>
<title><![CDATA[TI names Stryker CEO to board]]></title>
<description><![CDATA[Texas Instruments (NYSE: TXN) said Friday that Stephen MacMillan, president and chief executive officer of Stryker Corp., has joined the company&rsquo;s board of directors. (TXN) (SYK) (PHA) &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://feeds.bizjournals.com/~r/vertical_36/~3/339287626/daily49.html]]></link>
<pubDate>Fri, 18 Jul 2008 19:50:18 GMT</pubDate>
</item>
<item>
<title><![CDATA[Maker of ''Sinus Buster'' nasal spray acquired; further growth expected]]></title>
<description><![CDATA[SiCap LLC, a Colonie, N.Y., company known for its &quot;Sinus Buster&quot; pepper-based nasal sprays, has been acquired by Dynova Laboratories of Parsippany, N.J. &nbsp; <a href='http://www.feedzilla.com/'>Free RSS news feeds on Feedzilla</a>]]></description>
<link><![CDATA[ http://feeds.bizjournals.com/~r/vertical_36/~3/339265073/daily42.html]]></link>
<pubDate>Fri, 18 Jul 2008 18:53:31 GMT</pubDate>
</item>
<item>
<title><![CDATA[Folsom bank shrinks loss]]></title>
<description><![CDATA[Folsom Lake Bank lost $379,095 in the second quarter, down from a loss of $481,958 in the same three months of 2007. &nbsp; <a href='http://www.feedzilla.com/'>Free content on Feedzilla</a>]]></description>
<link><![CDATA[ http://feeds.bizjournals.com/~r/vertical_36/~3/339254917/daily57.html]]></link>
<pubDate>Fri, 18 Jul 2008 18:47:11 GMT</pubDate>
</item>
<item>
<title><![CDATA[Stocks to Watch: Stocks in focus for Monday]]></title>
<description><![CDATA[Financial and tech shares are likely to grab headlines with several industry leaders scheduled to release financial results, including Bank of America, American Express, Apple and Texas Instruments. &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.marketwatch.com/enf/rss.asp?guid=%7B70D17FA3-641B-46F4-9D87-C53D13DC5111%7D&siteid=rss]]></link>
<pubDate>Fri, 18 Jul 2008 17:36:00 -0500</pubDate>
</item>
<item>
<title><![CDATA[Special Report: Investors seek new failsafes as old safety nets look rickety]]></title>
<description><![CDATA[Thanks to oil and elections, some of the tried-and-true refuges from a battered stock market are showing signs of abandonment. &nbsp; <a href='http://www.feedzilla.com/'>Free RSS news feeds on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.marketwatch.com/enf/rss.asp?guid=%7B9B4DE220-D841-4853-BFE8-203E4EB2A7EC%7D&siteid=rss]]></link>
<pubDate>Fri, 18 Jul 2008 17:15:00 -0500</pubDate>
</item>
<item>
<title><![CDATA[PharmEng International Inc.: PharmEng Receives Site License From Health Canada To Manufacture Natural Health Products In Sydney, Nova Scotia]]></title>
<description><![CDATA[TORONTO, ONTARIO (MARKET WIRE)  PharmEng International Inc. (''PharmEng'') (TSX VENTURE: PII), today announced that its wholly owned subsidiary, Keata Pharma Inc. (''Keata''), received a site license issued by the Minister of Health under the authority of the Natural Health Products Regulations for the manufacturing, packaging and labelling of natural health products at its manufacturing facility located in Sydney, Nova Scotia. This site licence is subsequent to the drug establishment license received by the same manufacturing facility on June 26, 2008 that was previously announced in a press released dated July 8, 2008. &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www2.marketwire.com/mw/release_html_b1?release_id=417307&tsource=3]]></link>
<pubDate>Fri, 18 Jul 2008 16:45:00 GMT</pubDate>
</item>
<item>
<title><![CDATA[Biotech Stocks: Teva, Barr climb on merger deal]]></title>
<description><![CDATA[Drug stocks trade mixed, while shares of Israel's Teva and U.S. Barr gain on news they plan to merge. &nbsp; <a href='http://www.feedzilla.com/'>Free RSS news feeds on Feedzilla</a>]]></description>
<link><![CDATA[ http://www.marketwatch.com/enf/rss.asp?guid=%7BBB693D6E-F162-4B35-99EC-08C172DF4235%7D&siteid=rss]]></link>
<pubDate>Fri, 18 Jul 2008 14:25:00 -0500</pubDate>
</item>
<item>
<title><![CDATA[Addex Pharmaceuticals: Addex First Half 2008 Financial Results Monday, July 28]]></title>
<description><![CDATA[GENEVA, SWITZERLAND (MARKET WIRE)  Addex Pharmaceuticals Ltd. (SWX: ADXN) will discuss its financial results for the first half of 2008 and give a pipeline update during a teleconference and webcast for investors, analysts and the media on Monday, July 28 at 16:00 CET. &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www2.marketwire.com/mw/release_html_b1?release_id=417224&tsource=3]]></link>
<pubDate>Fri, 18 Jul 2008 13:55:00 GMT</pubDate>
</item>
<item>
<title><![CDATA[IDenta Corp.: CEO of International Drug & Explosives Detection Firm IDenta Issues Statement Admonishing Speculators for Damaging the Company's Reputation]]></title>
<description><![CDATA[JERUSALEM (MARKET WIRE)  IDenta Corp. (PINKSHEETS: IDTA) -- The CEO of IDenta Corp. today issued a comprehensive statement concerning recent unauthorized promotional activities it believes are being conducted by a small number of financial agencies and short-term stock speculators. The company believes that these actions have both damaged its reputation and unrightfully depreciated the value of the company's stock. In the statement IDenta reiterated that sales of the company's products are steadily increasing (since beginning of 2007), that numerous new products are in development (precursors), that the company &nbsp; <a href='http://www.feedzilla.com/'>Free news widgets on Feedzilla</a>]]></description>
<link><![CDATA[ http://www2.marketwire.com/mw/release_html_b1?release_id=417197&tsource=3]]></link>
<pubDate>Fri, 18 Jul 2008 13:15:00 GMT</pubDate>
</item>
<item>
<title><![CDATA[DUSA Pharmaceuticals, Inc.: DUSA Announces Update on Nicomide(R) Status]]></title>
<description><![CDATA[WILMINGTON, MASSACHUSETTS (MARKET WIRE)  DUSA Pharmaceuticals, Inc.(R) (NASDAQ GM: DUSA) reported today that Nicomide(R), a vitamin-mineral product currently prescribed by dermatologists, will no longer be manufactured and marketed as a prescription product.  The decision comes as a proactive action in response to discussions with the Food and Drug Administration (FDA). &nbsp; <a href='http://www.feedzilla.com/'>Free content on Feedzilla</a>]]></description>
<link><![CDATA[ http://www2.marketwire.com/mw/release_html_b1?release_id=417208&tsource=3]]></link>
<pubDate>Fri, 18 Jul 2008 13:00:00 GMT</pubDate>
</item>
</channel>
</rss>
